PT  - JOURNAL ARTICLE
AU  - YUKI MUKAI
AU  - YUMIKO MINAGAWA
AU  - HIROMI INOUE
AU  - AKIKO SATO
AU  - KENGO MATSUI
AU  - TAKANORI FUKUDA
AU  - KAZUYA ONUMA
AU  - HIDEYUKI HONGO
AU  - RYOSUKE SHIRATA
AU  - HIRONORI NAGATA
AU  - HARUMITU HASHIMOTO
AU  - TOMIO INOUE
AU  - MASAHARU HATA
AU  - MOTOKO OMURA
TI  - Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer
AID  - 10.21873/invivo.12177
DP  - 2020 Nov 01
TA  - In Vivo
PG  - 3387--3398
VI  - 34
IP  - 6
4099  - http://iv.iiarjournals.org/content/34/6/3387.short
4100  - http://iv.iiarjournals.org/content/34/6/3387.full
SO  - In Vivo2020 Nov 01; 34
AB  - Background/Aim: This study aimed to evaluate the clinical outcome of intensity-modulated radiation therapy (IMRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT) in uterine cervical cancer (UCC). IMRT consisted of whole-pelvic radiation therapy (WPRT) and sequential WPRT with central-shielding (WPRT-CS). Patients and Methods: Thirty UCC patients treated with IMRT using TomoTherapy, were retrospectively analyzed. Results: The median dose of WPRT and WPRT-CS was 36 and 14.4 Gy and the median total dose of these was 50 Gy in 25 fractions (Fr). Median HDR-ICBT dose/Fr to Point A was 25 Gy/5 Fr. Median 2 Gy per fraction-equivalent dose (EQD2) of combined WPRT and HDR-ICBT to Point A (α/β=10) was 71.0 Gy. The 3-year local control, disease-free survival, and overall survival rates were 89.9%, 83.3%, and 86.3%. Conclusion: IMRT of WPRT and WPRT-CS given in combination with HDR-ICBT was a feasible therapy resulting in good disease control and tolerance in patients with UCC.